Status:
COMPLETED
Role of IV Calcium to Prevent Diltiazem-related Hypotension
Lead Sponsor:
Haseki Training and Research Hospital
Conditions:
Atrial Fibrillation
Rapid Ventricular Response
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The objective of this study is to examine the efficacy and safety of IV calcium pretreatment at varying doses prior to weight-adjusted IV Diltiazem on the incidence of Diltiazem-related hypotension in...
Detailed Description
Patients were randomly divided into one of three groups. We assessed the Systolic Blood Pressure and Heart Rate of participants before treatment and 5, 10, and 15 min after treatment among the patient...
Eligibility Criteria
Inclusion
- Patients aged ≥ 18 years
- Patients with documented AFib/AFL (confirmed by ECG)
- Patients with a Heart Rate of ≥ 120 bpm, and a Systolic Blood Pressure of ≥ 90 mmHg
Exclusion
- Patients under 18 years of age
- pregnant individuals
- Patients with hemodynamic instability requiring electrocardioversion
- Patients with a documented history of sick sinus syndrome, third-degree AV block, Wolff-Parkinson-White syndrome
- Patients with hypotension (SBP \<90 mmHg)
- Patients with known or suspected hypercalcemia
- Patients with a confirmed allergy to diltiazem
- Patients with concurrent use of another Heart Rate control agent (such as beta-blockers, amiodarone, or digoxin) on the same admission
Key Trial Info
Start Date :
January 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2024
Estimated Enrollment :
217 Patients enrolled
Trial Details
Trial ID
NCT06494007
Start Date
January 1 2023
End Date
July 1 2024
Last Update
July 11 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Haseki Training and Research Hospital
Istanbul, Fatih, Turkey (Türkiye), 34265